PHAT - Phathom Pharma concludes enrollment in vonoprazan late-stage study in erosive esophagitis

Phathom Pharmaceuticals (PHAT) has completed patient enrollment in Phase 3 (PHALCON-EE) trial, evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis as well as the relief of heartburn. Phathom exceeded the patient enrollment target of 1,000 patients, and is on track to report topline results in 2H of 2021.Erosive esophagitis isnflammation that damages the tube running from the throat to the stomach (oesophagus).First phase of the trial is evaluating the efficacy and safety of vonoprazan 20 mg compared to lansoprazole 30 mg for the healing of EE for up to eight weeks. The second phase of the trial is evaluating the efficacy and safety of vonoprazan 10 mg QD and 20 mg QD compared to lansoprazole 15 mg QD for the maintenance of healing of EE for 24 weeks. Both phases will also evaluate relief of heartburn symptoms.Second vonoprazan Phase 3 study, PHALCON-HP is evaluating vonoprazan in combination

For further details see:

Phathom Pharma concludes enrollment in vonoprazan late-stage study in erosive esophagitis